Home > Formulary : Adult > Recent Decisions > 2018 >
Decisions 10th April 2018
At the meeting that took place on 10th April, the following decisions were agreed:
New Drug Requests
Approved
Fobumix Easyhaler® (budesonide/formoterol)
- Approved for inclusion onto the formulary for asthma and COPD. DuoResp Spiromax® to be made non-formulary
Not Approved
Apixaban
- Not approved for inclusion onto the formulary for patients undergoing mitral valve repairs and tissue mitral valve replacements
Shared Care Protocols/TLS Change in Status
Dymista® Nasal Spray (TLS amber to green)
- The extra evidence provided was discussed and it was concluded it did not demonstrate dymista nasal spray to be more effective than other sprays on the formulary or reduce referrals. To remain TLS amber.
Quinagolide (TLS red to amber)
- Change of TLS from red to amber 3 months agreed
Testosterone undecanoate (Nebido®) and testosterone decanoate, isocaproate, phenylpropionate and propionate (Sustanon®)
- New SCPs brought to meeting, however clarification of time frame for measuring testosterone levels required before can be agreed
Azathioprine
- Updated SCP and advise sheet approved
Hydroxychloroquine
- Updated SCP and advise sheet approved
Riluzole
- Updated SCP approved
Modafinil (TLS red to amber)
- Change of TLS from red to amber 3 months, SCP agreed
Levodopa,carbidopa and entacapone combined tablet
- Updated SCP approved
Entacapone
- Updated SCP approved
Other
Fiasp®
- The JFG agreed the use of Fiasp® for patients requiring multiple injections where post-prandial hyperglycaemia is a particular problem.